^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DM005

    i
    Other names: DM005, YH013, DM-005, DM 005, YH-013, YH 013
    Company:
    Biocytogen, Doma Pharma
    Drug class:
    Topoisomerase I inhibitor, EGFR-targeted antibody-drug conjugate, c-MET-targeted antibody-drug conjugate
    Related drugs:
    3ms
    A phase I, multicenter, open-label, first-in-human, dose escalation and expansion study of DM005 in patients with advanced solid tumors (ChiCTR2500095720)
    P1, N=176, Not yet recruiting, Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences); Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sci
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR wild-type
    |
    DM005
    5ms
    A Study of DM005 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=136, Recruiting, Doma Biopharmaceutical（Suzhou）Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    DM005
    11ms
    A Study of DM005 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=136, Not yet recruiting, Doma Biopharmaceutical（Suzhou）Co., Ltd.
    New P1 trial • Metastases
    |
    DM005
    over2years
    YH013, a novel EGFR x MET bispecific antibody-drug conjugate, exhibits potent antitumor efficacy (AACR 2023)
    Moreover, in multiple patient-derived xenografts of NSCLC and pancreatic ductal adenocarcinoma (PDAC), which co-express EGFR and MET, YH013 demonstrated superior and durable efficacy that outperformed benchmark antibodies at a lower dose (3 mg/kg). Collectively, these results suggest that YH013 can be an effective treatment option for EGFR and MET co-expressing tumors and overcome MET-driven EGFR-TKI resistance to improve patient outcomes.
    Clinical
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • EGFR expression • MET expression • EGFR H1975 • EGFR expression + MET expression
    |
    DM005